Search
Descriptor English: Inotuzumab Ozogamicin
Descriptor Spanish: Inotuzumab Ozogamicina
Descriptor inotuzumab ozogamicina
Entry term(s) Besponsa
Scope note: Inmunotoxina constituida por un anticuerpo monoclonal humanizado anti-CD22 (ANTÍGENO CD22) unido de forma covalente al antibiótico antineoplásico CALICHEAMICINA. Se utiliza para el tratamiento de adultos con LEUCEMIA LINFOBLÁSTICA AGUDA de precursores de los linfocitos B recidivante o resistente al tratamiento.
Descriptor Portuguese: Inotuzumab Ozogamicina
Descriptor French: Inotuzumab ozogamicine
Entry term(s): Besponsa
CMC 544
CMC-544
CMC544
Tree number(s): D09.408.051.247.750
D12.776.124.486.485.114.224.060.794
D12.776.124.790.651.114.224.060.794
D12.776.377.715.548.114.224.200.794
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D000080045
Scope note: Immunotoxin that consists of anti-CD22 (CD22 ANTIGEN) humanized monoclonal antibody covalently linked to the antineoplastic antibiotic CALICHEAMICIN. It is used for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (LEUKEMIA, ACUTE LYMPHOBLASTIC).
Allowable Qualifiers: AD administration & dosage
AE adverse effects
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
DE drug effects
EC economics
GE genetics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
TO toxicity
TU therapeutic use
UL ultrastructure
UR urine
Pharm Action: Antineoplastic Agents, Immunological
Antibiotics, Antineoplastic
Immunotoxins
Registry Number: P93RUU11P7
Public MeSH Note: 2020; INOTUZUMAB OZOGAMICIN was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2012-2019 and under ANTIBODIES, MONOCLONAL (2004-2011)
History Note: 2020 (2004)
DeCS ID: 59131
Unique ID: D000080045
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 2020/01/01
Date of Entry: 2019/07/08
Revision Date: 2019/01/16
Inotuzumab Ozogamicin - Preferred
Concept UI M0482497
Scope note Immunotoxin that consists of anti-CD22 (CD22 ANTIGEN) humanized monoclonal antibody covalently linked to the antineoplastic antibiotic CALICHEAMICIN. It is used for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (LEUKEMIA, ACUTE LYMPHOBLASTIC).
Preferred term Inotuzumab Ozogamicin
Besponsa - Narrower
Concept UI M000646240
Preferred term Besponsa
CMC544 - Narrower
Concept UI M0458356
Preferred term CMC544
Entry term(s) CMC 544
CMC-544



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey